ReviewPurinergic signalling2015
Blood cells: an historical account of the roles of purinergic signalling.
Review in Purinergic signalling, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 73 citations in OpenAlex.
- Altered extracellular ATP, ADP, and AMP hydrolysis in blood serum of sedentary individuals after an acute, aerobic, moderate exercise session.Molecular and cellular biochemistry · 2017Trial
- Responsiveness to adenosine diphosphate on carotid arterial and platelet functions in type 2 diabetic Otsuka Long-Evans Tokushima Fatty rats.Purinergic signalling · 2026Article
- Estudo Abrangente do Resveratrol Associado à Sulfadiazina em Linfócitos Infectados com Toxoplasma gondii: Envolvimento da Sinalização Purinérgica na Resposta Imunológica.Acta parasitologica · 2026Article
- Identification of purinergic system components in the venom of Bothrops mattogrossensis and the inhibitory effect of specioside extracted from Tabebuia aurea.Purinergic signalling · 2025Article
- Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation.Purinergic signalling · 2024Review
- Effects of uridine and nucleotides on hemostasis parameters.Journal of thrombosis and thrombolysis · 2023Article
- Article
- Novel possibility for cutaneous melanoma treatment by means of rosmarinic acid action on purinergic signaling.Purinergic signalling · 2022Review
- Metabolic Influences Modulating Erythrocyte Deformability and Eryptosis.Metabolites · 2021Review
- Purinergic interplay between erythrocytes and platelets in diabetes-associated vascular dysfunction.Purinergic signalling · 2021Review
- Using the Zebrafish as a Genetic Model to Study Erythropoiesis.International journal of molecular sciences · 2021Review
- Thrombo-Inflammation: A Focus on NTPDase1/CD39.Cells · 2021Review
- Diabetes and hypertension: Pivotal involvement of purinergic signaling.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Modulation of Cardiopulmonary Toxicity and Oxidative Stress by Phenolic-Rich Fraction of Croton zambiscus Leaves in Rat Exposed to Chronic Mixture of Environmental Toxicants.Cardiovascular toxicology · 2021Article
- ADP receptor P2y12 prevents excessive primitive hematopoiesis in zebrafish by inhibiting Gata1.Acta pharmacologica Sinica · 2021Article
- Pannexin 1 channels control the hemodynamic response to hypoxia by regulating OAmerican journal of physiology. Heart and circulatory physiology · 2021Article
- Guanosine, a guanine-based nucleoside relaxed isolated corpus cavernosum from mice through cGMP accumulation.Purinergic signalling · 2020Article
- Characterization of the NPurinergic signalling · 2020Article
- Innate immunity orchestrates the mobilization and homing of hematopoietic stem/progenitor cells by engaging purinergic signaling-an update.Purinergic signalling · 2020Review
- The role of purinergic P2YPurinergic signalling · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The involvement of purinergic signalling in the physiology of erythrocytes, platelets and leukocytes was recognised early. The release of ATP and the expression of purinoceptors and ectonucleotidases on erythrocytes in health and disease are reviewed. The release of ATP and ADP from platelets and the expression and roles of P1, P2Y(1), P2Y(12) and P2X1 receptors on platelets are described. P2Y(1) and P2X(1) receptors mediate changes in platelet shape, while P2Y(12) receptors mediate platelet aggregation. The changes in the role of purinergic signalling in a variety of disease conditions are considered. The successful use of P2Y(12) receptor antagonists, such as clopidogrel and ticagrelor, for the treatment of thrombosis, myocardial infarction and stroke is discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.